首页> 外文期刊>Pathophysiology of haemostasis and thrombosis >Evolution of Thrombin Formation and Fibrinolysis Markers, Including Thrombin-Activatable Fibrinolysis Inhibitor, during Severe Meningococcemia
【24h】

Evolution of Thrombin Formation and Fibrinolysis Markers, Including Thrombin-Activatable Fibrinolysis Inhibitor, during Severe Meningococcemia

机译:严重脑膜炎球菌血症期间凝血酶形成和纤溶标记物(包括凝血酶激活的纤溶抑制剂)的演变

获取原文
获取原文并翻译 | 示例
       

摘要

A 17-year-old girl presented with Neisseria meningitidis sepsis, with evidence of disseminated intravascular coagulation. Substitution therapy with both antithrombin and protein C concentrates was initiated, leading to clinical and biological improvement. Sequential dosages were performed for biological markers including thrombin-activatable fibrinolysis inhibitor (TAFI). Substitution therapy with both antithrombin and protein C concentrates led to a clinical and biological improvement. Biological markers showed a decrease in thrombin generation and in plasminogen activator inhibitor 1 (PAI-1) and a return of TAFI to a normal value. Discontinuation of substitutive treatment was marked by a clinical relapse at 24 h, with thrombin generation and increase in PAI-1, while TAFI remained unchanged. This report shows the evolution of hemostasis markersduring septicshockand provides new data concerning the effects of a substitutive therapy.
机译:一名17岁的女孩患有脑膜炎奈瑟氏菌败血症,有弥散性血管内凝血的证据。开始使用抗凝血酶和浓缩蛋白C的替代疗法,从而导致临床和生物学上的改善。对包括凝血酶可激活的纤维蛋白溶解抑制剂(TAFI)在内的生物标志物进行了连续剂量。抗凝血酶和蛋白C浓缩物的替代治疗导致临床和生物学上的进步。生物标志物显示凝血酶的生成和纤溶酶原激活物抑制剂1(PAI-1)减少,TAFI恢复至正常值。替代治疗的中断以24小时临床复发为标志,凝血酶产生并增加PAI-1,而TAFI保持不变。该报告显示了败血性休克过程中止血标志物的演变,并提供了有关替代疗法作用的新数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号